Biomedical subjects

M Privitera

Publications and source records attributed to M Privitera.

21 records · Page 2Linked to original sources

PubMed1989

Axonal regeneration on mature human brain tissue sections in culture.

Fresh frozen sections of the temporal lobe from patients undergoing surgical resection for the control of epilepsy were used as a substrate in tissue culture to test for neurite growth-promoting activity. Robust neurite growth from ganglia of embryonic chicks was observed on gray matter regions of the sections and little growth was observed on white matter regions. These results indicate that the dichotomy between gray and white matter regions of the mature central nervous system in supporting neurite growth is present in human brain tissue and supports the general hypothesis that white matter in the mature central nervous system inhibits neurite regeneration but that gray matter will support neurite growth.

Animals↗

PubMed1985

Assessment of suicide risk in patients with personality disorder and major affective diagnosis.

Mortality reviews conducted by the quality assurance committee in the Department of Psychiatry at the University of Rochester Medical Center during 1982-1984 disclosed a pattern of suicides by patients with a combination of major depression and either mixed or borderline personality disorder. This finding coincides with earlier published research on suicide risk for such patients. Data from the reviews led to the establishment of a suicide prevention task force and to changes in policies regarding patient transfers, family therapy, discharge planning, and suicide risk assessment. The data also suggest several hypotheses for further research on suicide risk assessment and case management for this patient population.

Adult↗

PubMedDate not supplied

Effects of the evening i.v. administration of erythropoietin in haemodialyzed patients.

The authors evaluated the possibility that the time of the administration of erythropoietin (rHuEPO) may play any effect on the therapeutic outcome of the treatment. The study was carried out on 26 uremic subjects submitted to hemodialysis in the morning or in the evening. At the end of the dialytic treatment every patient was administered rHuEPO IV. The amount of erythropoietin needed to reach an Ht value of 32% was evaluated. The subjects whose rHuEPO had been administered in the first evening hours showed that they needed a less quantity of rHuEPO (885 +/- 50 vs 1550 +/- 75 IU/Kg; p < 0.01), and showed a more rapid improvement of the anemia. According to the lans of a physiologic circadian rhythm, the evening i.v. administration of rHuEPO seems to insure a quicker therapeutic success.

Aged↗